Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05984784 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
A Phase 1 study, sponsored by Inmagene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05984784 is a Phase 1 study that was terminated before completion, run by Inmagene. The registered enrollment target is 13 participants.
The verdict
NCT05984784, a Phase 1 study, was terminated before completion, sponsored by Inmagene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.
Interventions
- DRUG Placebo
- DRUG IMG-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-08-09 |
| Est. Completion | 2024-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05984784
The ClinicalTrials.gov registry entry for NCT05984784 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inmagene, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05984784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05984784 about?
NCT05984784 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)". The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.
What is the current status of trial NCT05984784?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2023-08-09. Estimated completion is 2024-04-26.
What interventions are being tested in trial NCT05984784?
The interventions under investigation include: Placebo (DRUG), IMG-007 (DRUG).
Who is sponsoring clinical trial NCT05984784?
This trial is sponsored by Inmagene, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.